{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 122 of 169', 'Main assessments', 'Investigator assessments', \"Investigator's Global Assessment (IGA).\", 'Eczema Area and Severity Index (EASI).', 'Scoring Atopic Dermatitis (SCORAD).', 'Subject assessments', 'A total of 12 patient-reported outcomes (PROs) will be collected. The', 'following 5 PROs will be assessed on a daily basis using an electronic diary:', 'Worst Daily Pruritus NRS, Average Daily Pruritus NRS, Eczema-related Sleep', 'NRS, Patient Global Impression of Bother (PGI-B), and Patient Global', 'Impression of Severity (PGI-S).', 'The following 7 PROs will be completed at the trial site during visits: Patient', 'Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI),', 'EQ 5D 5L, SF 36 (acute recall), Work Productivity and Activity Impairment -', 'General Health (WPAI GH), Hospital Anxiety and Depression Scale (HADS),', 'and Treatment Satisfaction Questionnaire for Medicine (TSQM).', 'Safety assessments', 'Vital signs, physical examination, ECG, laboratory testing, pharmacokinetics', '(PK), anti-drug antibodies, and adverse event reporting.', 'Other assessments', 'Assessment of skin colonisation with Staphylococcus aureus, skin microbiome', 'characterisation, serum biomarkers, skin biopsies, photographs.', 'Primary endpoints', 'IGA score of 0 (clear) or 1 (almost clear) at Week 16.', 'EASI75 at Week 16.', 'Secondary', 'Secondary endpoints', 'endpoints', 'Change in SCORAD from baseline to Week 16.', 'Reduction of Worst Daily Pruritus NRS (weekly average) of at least 4', 'from baseline to Week 16.', 'Change in DLQI score from baseline to Week 16.', 'Additional secondary endpoints', 'AE/SAE frequency by preferred term.', 'Frequency of anti-drug antibodies.', 'EASI50 at Week 16.', 'EASI90 at Week 16.', 'Change from baseline to Week 16 in EASI score.', 'SCORAD75 at Week 16.', 'SCORAD50 at Week 16.', 'Change from baseline to Week 16 in Worst Daily Pruritus NRS', '(weekly average).', 'Reduction of Worst Daily Pruritus NRS (weekly average) of at least 3', 'from baseline to Week 16.', 'Reduction from baseline to Week 16 of DLQI of >4 points among', 'subjects with baseline DLQI >4.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 123 of 169', 'Secondary', 'Maintenance endpoints', 'endpoints', 'IGA of 0/1 at Week 52 among subjects with IGA of 0/1 at Week 16', '(continued)', 'achieved without rescue medication after initial randomisation to', 'tralokinumab.', 'EASI75 at Week 52 among subjects with EASI75 at Week 16 achieved', 'without rescue medication after initial randomisation to tralokinumab.', 'Statistical methods', 'Primary endpoints', 'The difference in response rates between treatment groups will be analysed', 'using the Cochran-Mantel-Haenszel test stratified by region and disease', 'severity.', 'The primary endpoints will be tested sequentially at a 5% significance level.', 'First IGA 0/1 and, if significant, EASI75. If both primary null hypotheses are', 'rejected, the secondary endpoints will be tested.', 'Secondary endpoints', 'The change from baseline to Week 16 in SCORAD will be analysed using a', 'repeated measurements model on the post baseline responses up to Week 16.', 'Reduction of Worst Daily Pruritus NRS weekly average of at least 4 is a binary', 'endpoint, and as such it will be analysed as described for the primary endpoint.', 'Change from baseline to Week 16 in DLQI will be analysed the same way as', 'change in SCORAD.', 'Maintenance endpoints', 'The 4 hypotheses of primary interest for maintenance treatment will be tested', 'sequentially with the next hypothesis in the sequence only being tested if the', 'previous one was significant. The maintenance endpoints will be evaluated in', 'the following order:', 'No difference between Q2W and placebo for IGA 0/1 at Week 52.', 'No difference between Q2W and placebo for EASI75 at Week 52.', 'No difference between Q4W and placebo for IGA 0/1 at Week 52.', 'No difference between Q4W and placebo for EASI75 at Week 52.', 'For each endpoint (IGA 0/1 and EASI75 at Week 52) the estimated response', 'rates and corresponding 95% CIs, and the pairwise treatment differences will', 'be presented. The difference in response rates between treatment groups will be', 'analysed using the Cochran Mantel-Haenszel test stratified by region.', 'A multiple testing procedure to control the overall type 1 error rate for the trial', 'will be used.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}